Image source: Getty Images.
When it comes to serious adverse events in clinical trials, one could be a fluke. But as Regulus Therapeutics (NASDAQ: RGLS) discovered, if the same side effect happens a second time, the Food and Drug Administration often breaks out the stop sign.